Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by CaseyLon May 24, 2024 11:02am

232 Views

Post# 36055862

Thrilled with GOBLET

- Positive Data from pancreatic cancer patients in the GOBLET and REO-017 open-label trials showed meaningful improvements in survival

- An ORR of 62% was observed, representing a near tripling from historical controls; 7.2 mo mPFS, 10.6 mo interim mOS are ≥25% compared to historical control trials1-4

- GOBLET data indicate the treatment has been well tolerated with no safety concerns

- Translational data from GOBLET show that patients with increases in blood TILs showed a decrease in tumor volumes

- Registration-enabled study protocol being finalized after pelareorep selected for inclusion by GCAR $5M PanCAN grant to explore pelareorep/mFOLFIRINOX regimen, expecting Q2 2024 start

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario